The Individualized Accurate Diagnosis and Treatment of Chronic Objective Pulmonary Disease(COPD) Patients Based on Multidimensional Data

Overview

Chronic obstructive pulmonary disease (COPD) is known as progressive lung disease and the fourth leading cause of death worldwide. Despite valuable efforts, there is still no Individualized accurate diagnostic and prognostic tool for COPD. Hence, the investigators' research integrated multi-dimensional data of COPD patients, which may provide an invaluable bioinformatic resource for understanding the underlying molecular alterations that drive disease progression, with the goal of developing individualized accurate diagnostic and therapeutic inventions.

Full Title of Study: “The Individualized Accurate Diagnosis and Treatment, as Well as the Prevention of Acute Exacerbation of Chronic Objective Pulmonary Disease(COPD) Based on Multidimensional Data”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 16, 2022

Detailed Description

Chronic obstructive pulmonary disease (COPD) is known as progressive lung disease and the fourth leading cause of death worldwide. Acute exacerbations of COPD (AECOPD) is an important event of disease progression worsening in airway function and respiratory symptoms, bringing about respiratory failure, and increasing the rates of mortality. Despite valuable efforts, there is still no Individualized accurate diagnostic and prognostic tool for COPD. In this context, the investigators are to perform comprehensive transcriptomic, proteomic, metabonomic and exosome characterization of COPD patients and healthy controls. Biological samples of COPD participants, including blood, urine, stool, saliva, bronchoalveolar lavage fluid and clinical characteristics are going to be collected from the remaining materials of the routine clinical examination. And samples of healthy controls will be collected from the rest of the healthy examination practice. By integrating the multi-dimensional data, the investigators aim to elucidate the impact of molecular alterations driving phenotypic variation and to delineate the mechanisms of AECOPD for prospective exploration of personalized, precision-based clinical care.

Arms, Groups and Cohorts

  • SCOPD
    • Participants with stable COPD diagnosed according to GOLD criteria and hasn’t encountered acute exacerbations in the past six months, generally include outpatient clinical patient and community patients.
  • AECOPD
    • Participants with COPD diagnosed according to GOLD criteria and suffered from acute exacerbations, characterized by worsening clinical symptoms(such as acute worsening of dyspnea, and/or cough and sputum production, and/or increased sputum purulence) and positive laboratory biomarkers suggesting AECOPD (such as serum CRP and serum neutrophilia or eosinophilia) at the time of registering into the group, particularly include inpatient.
  • Smoking healthy controls
    • Participants with a smoking history of more than ten years and was in good health, characterized by negative chest radiograph and negative laboratory tests for cardiac, pulmonary or hematologic disorders, and so on.
  • Non smoking healthy controls
    • Participants without a smoking history and was in good health, characterized by negative chest radiograph and negative laboratory tests for cardiac, pulmonary or hematologic disorders, and so on.

Clinical Trial Outcome Measures

Primary Measures

  • The transcriptome analysis of participates’ serum or plasma
    • Time Frame: through study completion, an average of 1 year
    • Include the transcriptome data of serum,plasma or exosomes inside
  • The metabolomics analysis of participates’ urine or stool
    • Time Frame: through study completion, an average of 1 year
    • Predominately include metabolic target analysis, metabolic profiling analysis
  • The proteomics analysis of bronchoalveolar lavage fluid and saliva
    • Time Frame: through study completion, an average of 1 year
    • Differentially expressed proteins between SCOPD and AECOPD which associated with disease progression were analyesd

Participating in This Clinical Trial

Inclusion Criteria

1. Patient has signed informed consent. 2. Patients diagnosed with COPD or fully healthy participants. Exclusion Criteria:

1. Tumor disease. 2. Heart disease. 3. Thyroid disease.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Wuhan Union Hospital, China
  • Provider of Information About this Clinical Study
    • Principal Investigator: Yang Jin, Professor – Wuhan Union Hospital, China
  • Overall Contact(s)
    • Wei Geng, Master, +8618696152606, dr.geng116@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.